This content is from: Home

Introduction: Financing through understanding

IP's intangible nature does little to bolster investor confidence in biotechnology. Roya Ghafele, who works as an economist at WIPO, says that biotechnology is insufficiently funded due to a lack of awareness of the value of patents among both borrowers and investors

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial